Custom immune checkpoint antibody fragment discovery focuses on developing specialized antibody fragments that target immune regulatory pathways. These fragments, such as single-chain variable fragments (scFv) and fragment antigen-binding (Fab) regions, offer advantages like enhanced tissue penetration and reduced immunogenicity. Researchers use advanced platforms, including phage display and recombinant expression systems, to optimize fragment specificity and therapeutic potential.